Patients hospitalized with COVID-19 should receive pharmacologic thromboprophylaxis unless there is a contraindication to anticoagulation. Several studies have examined therapeutic and intermediate dose anticoagulation in critically and moderately ill patients to decrease mortality and/or the severity of COVID-19. Their results provide guidance on the effective and safe management of anticoagulation in hospitalized patients with COVID-19.
This presentation is by Dr Vicky Tagalakis, Montreal from the Thrombosis Canada annual conference 2021

свернуть